ArticleMedicine2025
Association between obesity and Bell's palsy by combining Mendelian randomization and network pharmacology.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe issue of obesity has emerged as a significant global health challenge; nevertheless, the association between Bell's palsy (BP) and obesity remains ambiguous. In this study, the Mendelian randomization (MR) approach was employed to investigate their relationship, while network pharmacology methods were utilized to unveil the underlying mechanisms.
methodsWe utilized single nucleotide polymorphisms closely linked to obesity and BP as instrumental variables for the MR analysis. Four robust bidirectional MR analysis methods, namely inverse variance weighting (IVW), weighted median, weighted mode, and MR-Egger were employed to assess the association between obesity and BP. Additionally, sensitivity analysis was conducted to evaluate levels of heterogeneity, sensitivity, and stability. Furthermore, we identified therapeutic targets associated with obesity and BP. Subsequently, a protein-protein interaction network analysis was conducted. Finally, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were employed to investigate potential mechanisms underlying the relationship between obesity and BP.
resultsThe IVW analysis demonstrated a significant positive correlation between obesity and BP (odds ratio [OR] = 1.267, 95% confidence interval [95% CI] = 1.049-1.530, P = .013). However, there was no evidence to suggest that BP increased the risk of obesity. Furthermore, network pharmacology analysis revealed that the 2 diseases shared a total of 712 common targets. GO enrichment analysis shows that this process mainly regulates chemical synaptic signal transmission by modulating receptor signaling factor activity, receptor ligand activity, etc. KEGG enrichment analysis shows that the EGFR/PI3K/Akt signaling pathway plays a significant role in this process.
conclusionOur study findings suggest that obesity may increase the risk of BP, and its underlying mechanism may potentially involve regulating chemical synaptic transmission through the EFGR/PI3K/Akt signaling pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.